<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542920340998">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">22.11.2018 20:59:00 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.18az2h7ua90m4</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I&apos;m on business &lt;a href=&quot;https://www.klevermedia.co.uk/hoffman-pharmacy-31f1.pdf&quot;&gt;hoffman pharmacy&lt;/a&gt;  Patients generally survive longer when the cancer is sensitive rather than resistant to chemotherapeutic drugs. Unfortunately, in many types of cancer, the response rate is often about 25 percent. The challenge is determining cancer sensitivity before treatment. While the test, developed by Precision Therapeutics Inc., has been available for years, it&apos;s been unclear whether it improved outcomes.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
